N-乙酰半胱氨酸保护异种移植人卵巢组织卵泡免受缺血再灌注损伤
该研究将28名23-36岁女性的冻融人卵巢组织移植至免疫缺陷小鼠,评估N-乙酰半胱氨酸(NAC)对缺血再灌注损伤的保护作用。每日腹腔注射150 mg/kg NAC 7-12天可上调抗氧化防御系统、发挥抗炎和抗凋亡效应,提高卵泡存活率。体外实验显示NAC浓度增加可显著上调抗氧化基因表达。
要点
- NAC腹腔注射7-12天可减少异种移植人卵巢组织的缺血再灌注损伤。
- NAC上调Sod1、Hmox1、Cat等抗氧化基因并降低炎症因子表达。
- NAC降低Bax/Bcl2比值和cleaved caspase-3免疫反应性,抑制凋亡。
核心结论
- 移植后每日给予NAC 7-12天可减轻人卵巢异种移植物缺血再灌注损伤并提高卵泡存活。
研究设计与样本
- 冻融人卵巢组织来自28名23-36岁女性,移植至免疫缺陷小鼠或体外培养。
- 短期异种移植研究(1周)每组12名患者,每日给生理盐水或150 mg/kg NAC共7天。
- 长期异种移植研究(4周)中,一组每组12名患者给生理盐水或150 mg/kg NAC共12天。
- 另一长期研究每组8名患者给50、150或300 mg/kg NAC共7天。
- 体外培养人卵巢组织(每组3名患者共12块)用0、5、25、75 mM NAC培养4天。
主要发现
- 1周移植后,NAC150组Sod1、Hmox1、Cat相对表达显著高于对照(P=0.04、P=0.03、P=0.01)。
- NAC150组Tnf-α、Il1-β、Il6表达降低,Bax/Bcl2比值显著降低(P<0.005)。
- 体外实验中SOD1、HMOX1、CAT表达随NAC浓度增加显著升高(均P<0.001)。
- 体外实验中VEGFA、ANGPTL4表达及BAX/BCL2比值随NAC浓度增加显著降低(P<0.02、P<0.001、P<0.001)。
- 4周移植后NAC150组胶原含量与对照相似(56.6%±2.2 vs 57.6%±1.8),CD31阳性血管面积显著减少(0.69%±0.08 vs 0.51%±0.07,P<0.02)。
关键数值与推荐
- 1周移植卵泡密度(个/mm3,均值±SD):对照19.5±26.3,NAC150组34.2±53.5。
- 4周移植卵泡密度:对照9.3±11.0,NAC150组14.4±15.0。
- NAC150组1周移植后卵泡密度较同一患者对照移植物增加约2倍。
- NAC150和NAC300组4周移植后卵泡密度增加约5倍。
临床怎么用
- NAC有望作为卵巢组织移植中保护卵泡免受缺血再灌注损伤的候选药物。
- 当前结果为NAC临床应用的初步步骤,需进一步研究不同给药途径以优化临床使用。
局限性
- 人卵巢皮质卵泡密度高度异质,同一女性不同皮质块间可相差100倍。
- 本研究治疗组内和组间、患者间卵泡密度变异大,无法得出确凿结论。
- 腹腔注射途径需研究其他给药途径以优化NAC的潜在临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can antioxidant treatment with N-acetylcysteine (NAC) protect ovarian follicles from ischemia-reperfusion injury in xenotransplanted human ovarian tissue? SUMMARY ANSWER: Daily administration of NAC for 7-12 days post-transplantation reduced ischemia-reperfusion injury and increased follicle survival in human ovarian xenografts by upregulating the antioxidant defense system and exerting anti-inflammatory and antiapoptotic effects. WHAT IS KNOWN ALREADY: Freezing of human ovarian tissue is performed with high follicular survival rates but up to 70% of follicles appear to be lost due to hypoxia and ischemia-reperfusion injury during ovarian tissue transplantation (OTT). NAC has been demonstrated to possess antioxidant and antiapoptotic properties, and studies in rodents have shown that intraperitoneal administration of NAC reduces ischemia-reperfusion injury and increases follicle survival in autotransplanted murine ovaries. STUDY DESIGN, SIZE, DURATION: Pieces of frozen-thawed human ovarian tissue from 28 women aged 23-36 years were transplanted to immunodeficient mice in short- and long-term xenograft studies or cultured in vitro. Three short-term xenograft studies (1-week duration) were performed, in which saline or 150 mg/kg NAC was administered for 7 days post-transplantation (n = 12 patients per group). Two long-term xenograft studies (4 weeks of duration) were performed. In one of these studies, saline or 150 mg/kg NAC was administered for 12 days (n = 12 patients per group), while in the other study 50, 150 or 300 mg/kg NAC was administered for 7 days (n = 8 patients per group). In addition, human ovarian tissue (n = 12 pieces from three patients per group) was cultured with increasing concentrations of NAC (0, 5, 25 and 75 mM) for 4 days in vitro. PARTICIPANTS/MATERIALS, SETTING, METHODS: Donated ovarian tissue was obtained from women who had undergone ovarian tissue cryopreservation for fertility preservation at the University Hospital of Copenhagen. Cortical tissue pieces (5 × 5 × 1 mm) were transplanted subcutaneously to immunodeficient mice and NAC or saline was injected intraperitoneally. Grafts were retrieved after 1 or 4 weeks and follicle density was assessed. Gene expression analysis of antioxidant defense markers (superoxide dismutase; Sod1/SOD1, heme oxygenase-1; Hmox1/HMOX1, catalase; Cat/CAT), proinflammatory cytokines (tumor necrosis factor-alpha; Tnf-α, interleukin-1-beta; Il1-β, interleukin 6; Il6), apoptotic factors (B-cell lymphoma 2; Bcl2/BCL2, Bcl-2-associated X protein; Bax/BAX) and angiogenic factors (vascular endothelial growth factor A; Vegfa/VEGFA, angiopoietin-like 4; Angptl4/ANGPTL4) was performed in 1-week-old human ovarian xenografts and in cultured human ovarian tissue. Grafts retrieved after 4 weeks were histologically processed and analyzed for vascularization by CD31 immunohistochemical staining, fibrosis by Masson's Trichrome staining and apoptosis by immunofluorescence using cleaved caspase-3. MAIN RESULTS AND THE ROLE OF CHANCE: After 1-week grafting, the relative expression of Sod1, Hmox1 and Cat was significantly higher in the group receiving 150 mg/kg NAC (NAC150-treated group) compared to controls (P = 0.04, P = 0.03, and P = 0.01, respectively), whereas the expression levels of Tnf-α, Il1-β and Il6 were reduced. The Bax/Bcl2 ratio was also significantly reduced in the NAC150-treated group (P < 0.005). In vitro, the relative gene expression of SOD1, HMOX1 and CAT increased significantly in the human ovarian tissue with increasing concentrations of NAC (P < 0.001 for all genes). However, the expression of VEGFA and ANGPTL4 as well as the BAX/BCL2 ratio decreased significantly with increasing concentrations of NAC (P < 0.02, P < 0.001 and P < 0.001, respectively). After 4-week grafting, fibrosis measured by collagen content was similar in the NAC150-treated group compared to controls (control: 56.6% ± 2.2; NAC150: 57.6% ± 1.8), whereas a statistically significant reduction in the CD31-positive vessel area was found (control: 0.69% ± 0.08; NAC150: 0.51% ± 0.07; P < 0.02). Furthermore, a reduced immunoreactivity of cleaved caspase-3 was observed in follicles of the NAC150-treated xenografts compared to controls. Follicle density (follicles/mm3, mean ± SD) was higher in the NAC150-treated group compared to the control group in the 1-week xenografts (control: 19.5 ± 26.3; NAC150: 34.2 ± 53.5) and 4-week xenografts (control: 9.3 ± 11.0; NAC150: 14.4 ± 15.0). Overall, a 2-fold increase in follicle density was observed in the NAC150-group after 1-week grafting where fold changes in follicle density were calculated in relation to grafts from the same patient. Around a 5-fold increase in follicle density was observed in the NAC150 and NAC300 groups after 4-week grafting. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Follicle density in the human ovarian cortex is highly heterogeneous and can vary 100-fold between cortex pieces from the same woman. A high variability in follicle density within and between treatment groups and patients was found in the current study. Thus, solid conclusions cannot be made. While intraperitoneal injections of NAC appeared to reduce ischemia-reperfusion injury in human ovarian xenografts, different administration routes should be investigated in order to optimize NAC for potential clinical use. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study to demonstrate the antioxidant, anti-inflammatory and antiapoptotic properties of NAC in xenotransplanted human ovarian tissue. Therefore, NAC appears to be a promising candidate for protecting ovarian follicles from ischemia-reperfusion injury. This provides the initial steps toward clinical application of NAC, which could potentially reduce the loss of ovarian follicles following OTT. STUDY FUNDING/COMPETING INTEREST(S): We are grateful to the Danish Childhood Cancer Foundation, Hørslev Foundation, Aase and Einar Danielsen's Foundation (grant number: 10-001999), Dagmar Marshalls Foundation, Else and Mogens Wedell-Wedellsborgs Foundation, Knud and Edith Eriksens Mindefond, and Fabrikant Einar Willumsens Mindelegat for funding this study. None of the authors have any competing interests to declare.
引用
- Olesen HØ, Pors SE, Jensen LB, et al. N-acetylcysteine protects ovarian follicles from ischemia-reperfusion injury in xenotransplanted human ovarian tissue. Hum Reprod. 2021. PMID: 33246336. doi:10.1093/humrep/deaa291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。